Decitabine plus R-CHOP for EBV-positive DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that is linked to the Epstein-Barr virus (EBV).
- You must not have had any chemotherapy or other lymphoma treatment before.
- You must be at least 18 years old and under 80 years old.
- You must have a tumor that is at least 1.5 cm on one side and have enough tissue for special testing.
- You cannot have lymphoma that has spread to your brain or spinal cord.
- You cannot have a serious infection like HIV, active hepatitis B, or active hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a way to use your tumor's DNA (called ctDNA) to choose a targeted treatment for your newly diagnosed DLBCL. It aims to see if this personalized approach works better than standard care.
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
This trial tests a higher dose of the targeted drug rituximab combined with standard chemotherapy (R-CHOP) for men with newly diagnosed, advanced DLBCL. The goal is to see if this stronger dose works better than the usual dose for this type of lymphoma.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
Hear when a new Lymphoma, Large-Cell, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.